AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35512458
Drug: BGF 160/14.4/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGF 160/14.4/10 μg
Trial: 34182998
Drug: GFF 14.4/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFF 14.4/10 μg
Trial: 34182998
Drug: BFF 320/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BFF 320/10 μg
Trial: 33270487
Drug: Men-AC vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Men-AC vaccine
Trial: 33270487
Drug: Lanzhou-AC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanzhou-AC vaccine (Control)
Trial: 36004504
Drug: Intradermal BTX‐A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal BTX‐A injection (50‐65 U)
Trial: 36004504
Drug: Intradermal normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal normal saline (NS) injection
Trial: 36283748
Drug: Dim light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim light therapy
Trial: 32245464
Drug: Palovarotene 20
RxNorm normalized name: palovarotene
DrugBank: Palovarotene (DB05467)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palovarotene 20 mg/day for 4 weeks, then 10 mg/day for 8 weeks after left hip fracture surgery.
Trial: 32245464
Drug: Palovarotene 20
RxNorm normalized name: palovarotene
DrugBank: Palovarotene (DB05467)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palovarotene 20 mg/day started at fracture occurrence, continued for 4 weeks, then reduced to 10 mg/day for 8 weeks after right hip fracture surgery.
Trial: 35898773
Drug: Compound Danshen
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Danshen injection combined with magnesium sulfate
Trial: 33904664
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml of Mountain Dew® (caffeinated soft drink sweetened with high-fructose corn syrup)
Trial: 33904664
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml of tap water (H2O)
Trial: 36378553
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (1 g/day; 1.2:1 ratio of eicosapentaenoic to docosahexaenoic acid)
Trial: 34951021
Drug: Best standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best standard treatment (BST)
Trial: 34795952
Drug: Mirogabalin (clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirogabalin (clinical dose) added to conventional therapy (non-steroidal anti-inflammatory drugs and/or acetaminophen) for 8 weeks
Trial: 34795952
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (non-steroidal anti-inflammatory drugs and/or acetaminophen) without mirogabalin
Trial: 32725772
Drug: Cisplatin dose
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin dose per kilogram lean body mass (LBM) in the first course
Trial: 32725772
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (concurrent platinum–etoposide chemotherapy and thoracic radiotherapy)
Trial: 35804404
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (no treatment)
Trial: 34906334
Drug: Ponatinib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib (30 mg daily) with FLAG-IDA (fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor)
Trial: 34906334
Drug: Ponatinib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponatinib (30 mg daily) with FLAG-IDA
Trial: 33091752
Drug: L-carnitine (LC)
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-carnitine (LC) supplementation at 150 mg/kg/d for 12 weeks
Trial: 35569569
Drug: Oral motor
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral motor intervention combined with non-nutritive sucking
Trial: 33356011
Drug: Prazosin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (1 mg/day for 1 week)
Trial: 34856379
Drug: Standard-of-care treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care treatment (n = 36)
Trial: 33384915
Drug: Preventure intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preventure intervention delivered by school staff (two 90-minute group sessions incorporating cognitive-behavioural therapy and motivational interviewing)
Trial: 38581534
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors (AIs)
Trial: 34119421
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g flaxseed supplementation
Trial: 34119421
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g flaxseed supplementation
Trial: 34906295
Drug: EndoMT group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EndoMT group (no treatment)
Trial: 34906295
Drug: Blank group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blank group (no treatment)
Trial: 34565678
Drug: Bedinvetmab (0.5–1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedinvetmab (0.5–1.0 mg kg–1, n = 141)
Trial: 34565678
Drug: Bedinvetmab (0.5–1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedinvetmab (0.5–1.0 mg kg–1)
Trial: 32455620
Drug: DieTBra +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DieTBra + EVOO (52 mL/day)
Trial: 32455620
Drug: EVOO (52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVOO (52 mL/day)
Trial: 36382849
Drug: Pevonedistat 25
RxNorm normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pevonedistat 25 mg/m2
Trial: 36382849
Drug: Pevonedistat 50
RxNorm normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pevonedistat 50 mg/m2
Trial: 34044563
Drug: Ropivacaine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 10 mL
Trial: 34044563
Drug: Ropivacaine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 20 mL
Trial: 34044563
Drug: Ropivacaine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 30 mL
Trial: 35123662
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors (anastrozole, exemestane, or letrozole)
Trial: 35770520
Drug: Mazindol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mazindol (1 mg, twice a day for 6 months)
Trial: 35770520
Drug: Mazindol-metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mazindol-metformin (500 mg metformin combined with 1 mg mazindol, twice a day for 6 months)
Trial: 33074074
Drug: 1 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 × 10^6 conidia/ml suspension of Colletotrichum siamense
Trial: 36208293
Drug: Belimumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belimumab (10 mg/kg intravenous)
Trial: 33065817
Drug: Coping with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coping with Depression course with additional daily placebo treatment
Trial: 35597959
Drug: Self-guided digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-guided digital treatment comprising psychoeducation and virtual reality exposure therapy (VRET) for 6 weeks, including one therapy session preparing for VRET and 4 weeks of self-guided VRET.
Trial: 32858361
Drug: Positive airway
RxNorm normalized name: VersaPAP Positive Airway Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive airway pressure (PAP) therapy for at least three months (mean 377.6 ± 419.5 days)
Trial: 33483123
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU) - nine sessions
Trial: 36388237
Drug: Levodopa-Carbidopa Intestinal
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa-Carbidopa Intestinal Gel (LCIG)
Trial: 34236101
Drug: Oral Optimized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Optimized Medical Treatment (OMT)
Trial: 33405297
Drug: 140% Insulin-to-Carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140% Insulin-to-Carbohydrate Ratio (ICR)
Trial: 33405297
Drug: 160% Insulin-to-Carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160% Insulin-to-Carbohydrate Ratio (ICR)
Trial: 33405297
Drug: 100% Insulin-to-Carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% Insulin-to-Carbohydrate Ratio (ICR)
Trial: 33405297
Drug: 120% Insulin-to-Carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120% Insulin-to-Carbohydrate Ratio (ICR)
Trial: 33405297
Drug: Increasing insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increasing insulin doses (100%-160% ICR)
Trial: 32609651
Drug: Expectations toward
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectations toward treatment effects
Trial: 32609651
Drug: Unintentional unblinding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unintentional unblinding and patients' perception of treatment
Trial: 34267583
Drug: TG4 (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG4 (four weekly campus board training sessions)
Trial: 34267583
Drug: TG2 (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG2 (two weekly campus board training sessions)
Trial: 36320825
Drug: Withholding methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Withholding methotrexate for 2 weeks after each dose of ChAdOx1 nCov‐19 vaccine (MIVAC I)
Trial: 36320825
Drug: Withholding methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Withholding methotrexate for 2 weeks after the second dose of ChAdOx1 nCov‐19 vaccine (MIVAC II)
Trial: 35067125
Drug: Robotic assisted
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic assisted training (assisted motion, biofeedback, antagonist muscle vibration)
Trial: 36354243
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of magnesium daily (two 250-mg magnesium oxide tablets for five days)
Trial: 34881835
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide (Rybelsus®)
Trial: 35345663
Drug: Temozolomide single
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide single agent and doxorubicin
Trial: 35345663
Drug: Temozolomide capsules
RxNorm normalized name: Temozolomide Capsules
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide capsules (control group)
Trial: 34495437
Drug: Prophylactic anticonvulsant
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic anticonvulsant use in both aSAH and sICH
Trial: 34495437
Drug: Prophylactic anticonvulsant
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic anticonvulsant use only in aSAH
Trial: 34495437
Drug: Prophylactic anticonvulsant
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic anticonvulsant use only in sICH
Trial: 34495437
Drug: Prophylactic anticonvulsant
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic anticonvulsant use for all patients with aSAH
Trial: 34495437
Drug: Correct response
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correct response to AHA/ASA Guidelines on prophylactic anticonvulsants in sICH
Trial: 34382717
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of French maritime pine bark extract supplementation (Oligopin) with enteral nutrition for 10 days
Trial: 33221341
Drug: AB2 (affinity-matured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AB2 (affinity-matured recombinant Fab inhibitor)
Trial: 36411968
Drug: PMC split-dose
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMC split-dose regimen
Trial: 37533380
Drug: Trazpiroben 50
RxNorm normalized name: Trazpiroben
DrugBank: Trazpiroben (DB18794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazpiroben 50 mg
Trial: 33462988
Drug: Trazpiroben 10
RxNorm normalized name: Trazpiroben
DrugBank: Trazpiroben (DB18794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazpiroben 10 mg
Trial: 34805403
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hydroxyzine and clowns
Trial: 35193545
Drug: Enerisant 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enerisant 25 mg/day
Trial: 35193545
Drug: Enerisant 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enerisant 50 mg/day
Trial: 35193545
Drug: Enerisant 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enerisant 100 mg/day
Trial: 35193545
Drug: Enerisant 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enerisant 5 mg/day
Trial: 35193545
Drug: Enerisant 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enerisant 10 mg/day
Trial: 34957992
Drug: Combined handheld
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined handheld ultrasound and fluoroscopy-guided corticosteroid injection
Trial: 34957992
Drug: Conventional ultrasound-guided
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ultrasound-guided corticosteroid injection
Trial: 36235865
Drug: FibreMAX (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FibreMAX (two daily servings of 25 g of BARLEYmax®)
Trial: 36235865
Drug: FibreGRAD (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FibreGRAD (two daily servings with the amount of fibre gradually increased)
Trial: 36235865
Drug: Control (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (two daily servings totalling 25 g of placebo product)
Trial: 32140704
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplement 10 µg
Trial: 32140704
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplement 25 µg
Trial: 32140704
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 µg)
Trial: 35925203
Drug: Non‐Ach (beta‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐Ach (beta‐3 agonists)
Trial: 33512251
Drug: Honey-lemon spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honey-lemon spray
Trial: 33512251
Drug: Benzydamine hydrochloride
RxNorm normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzydamine hydrochloride spray
Trial: 33715382
Drug: TR‐PH (fixed-combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TR‐PH (fixed-combination tropicamide 1% and phenylephrine 2.5%)
Trial: 35553560
Drug: Heat Therapy
RxNorm normalized name: CVS Neck Arm & Leg Heat Therapy Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat Therapy (HT) at 39ºC for 30 min/day, 5 days/week during 3 consecutive weeks
Trial: 35553560
Drug: Heat Therapy
RxNorm normalized name: CVS Neck Arm & Leg Heat Therapy Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat Therapy (HT) at 39ºC for 3 weeks
Trial: 32398160
Drug: Nitrous oxide/oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrous oxide/oxygen plus intravenous acetaminophen (NOO-A)
Trial: 32907433
Drug: Intensive glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glycemic control with glycemic targets of fasting blood glucose (FBG) <130 mg/dL, postprandial BG <180 mg/dL, and HbA1c <8%, using a basal-bolus insulin regimen and frequent titration of insulin.
Trial: 32907433
Drug: Conventional glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glucose control with prior treatment (oral antidiabetic drugs) with no titration unless meeting rescue criteria.
Trial: 34391759
Drug: Low-dose radiation
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radiation therapy (LDRT) of 0.5 Gy to bilateral whole lungs
Trial: 34251534
Drug: Oral irrigator
RxNorm normalized name: Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral irrigator + toothbrush (OI group, n=15)
Trial: 34251534
Drug: Oral irrigator
RxNorm normalized name: Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral irrigator + toothbrush (OI group)
Trial: 33827834
Drug: Active Communication
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Communication Education (ACE) programme plus treatment‐as‐usual
Trial: 33827834
Drug: treatment‐as‐usual only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment‐as‐usual only (control group)
Trial: 32168417
Drug: Ultrasound acupuncture
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound acupuncture (pulsed therapeutic ultrasound at 1 MHz for 5 minutes per point daily for 12 days)
Trial: 35150943
Drug: Chitooligosaccharide (COS)
RxNorm normalized name: fructooligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitooligosaccharide (COS) 15 mg/kg
Trial: 35218559
Drug: Terbutaline (TER;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (TER; 4 mg × day-1, n = 13)
Trial: 36161487
Drug: Standard (control)
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard (control) treatment
Trial: 36120781
Drug: 10-mg/d Donepezil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg/d Donepezil Transdermal Delivery System (TDS)
Trial: 36120781
Drug: 5-mg/d Donepezil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mg/d Donepezil Transdermal Delivery System (TDS)
Trial: 36120781
Drug: Oral Donepezil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Donepezil (10-mg/d)
Trial: 37602418
Drug: Topical repellents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical repellents
Trial: 34192714
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (n=90)
Trial: 35361636
Drug: Group biofeedback
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group biofeedback treatment, psycho‐education and treatment as usual (TAU)
Trial: 35361636
Drug: Group biofeedback
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group biofeedback treatment, psycho‐education and TAU
Trial: 32848365
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C 1 g administered 10 minutes after induction of anesthesia, 10 minutes before cardiac reanimation, and at the moment of sternal closure
Trial: 32848365
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C 1 g administered
Trial: 33883048
Drug: Breast milk
RxNorm normalized name: BREAST MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast milk oral care
Trial: 34971214
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (pulsed transcranial and intraocular 1068nm near-infrared light)
Trial: 32149424
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg APT‐1011 BID
Trial: 32149424
Drug: 3.0 mg
RxNorm normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mg APT‐1011 QD
Trial: 33713384
Drug: Fibrinogen concentrate
RxNorm normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen concentrate (3 g)
Trial: 34238308
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day NMN
Trial: 34238308
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day NMN
Trial: 34238308
Drug: 1200 mg/day
RxNorm normalized name: Rebetron, single dose 1200 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg/day NMN
Trial: 35609974
Drug: Coated flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated flow diverter p64 MW HPC under single antiplatelet treatment (SAPT)
Trial: 35609974
Drug: Bare flow
RxNorm normalized name: urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bare flow diverter p64 MW under dual antiplatelet treatment (DAPT)
Trial: 34226917
Drug: Baseline models
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline models using five commonly used ML methods